Company news
BriaCell Therapeutics Corp news in 2025
BriaCell Therapeutics Corp's news releases, calls and decks from 2025, newest first.
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
December 18, 2025
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
December 10, 2025
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
December 9, 2025
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
December 9, 2025
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
December 2, 2025
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
November 25, 2025
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
November 20, 2025
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
November 18, 2025
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
November 7, 2025
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
November 4, 2025
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
October 22, 2025
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
October 21, 2025
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
October 21, 2025
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
October 20, 2025
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
October 13, 2025
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
October 3, 2025
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
August 26, 2025
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
August 25, 2025
BriaCell Announces Proposed Effective Date of Share Consolidation
August 21, 2025
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
August 13, 2025
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
July 31, 2025
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
July 30, 2025
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
July 29, 2025
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
July 25, 2025
BriaCell Therapeutics Announces Closing of $15 million Public Offering
July 16, 2025
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
July 15, 2025
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
July 15, 2025
BriaCell's Bria-IMT(TM) Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
July 11, 2025
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
July 11, 2025
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
July 10, 2025
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
July 9, 2025
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
July 8, 2025
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
July 2, 2025
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
June 24, 2025
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
June 4, 2025
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
June 2, 2025
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
May 27, 2025
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
May 23, 2025
BriaCell CEO Letter to Shareholders
May 20, 2025
BriaCell Reports "Late-Breaker" Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
April 30, 2025
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
April 30, 2025
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
April 28, 2025
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
April 28, 2025
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
April 24, 2025
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
April 24, 2025
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
April 23, 2025
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
April 22, 2025
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
April 16, 2025
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
April 10, 2025
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
March 26, 2025